Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8487881 | 0.95 | POLB (0.47) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL3133715 | 0.85 | BRD4 (0.49) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL3146438 | 0.84 | KMT2A (0.46) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL2574235 | 0.79 | KMT2A (0.55) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL423037 | 0.78 | CA2 (0.68) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL1244793 | 0.78 | — | — | |
| SCHEMBL18109243 | 0.77 | KEAP1 (0.71) | POLBKDM4ECA2CA12CA1 | |
| Hydrochloric Acid SCHEMBL3516886 | 0.76 | CA2 (0.65) | POLBKDM4ETSHRRECQLKMT2A | |
| SCHEMBL11512465 | 0.76 | CA2 (0.65) | POLBKDM4ETSHRRECQLKMT2A | |
| Hydrochloric Acid SCHEMBL4574707 | 0.76 | CA2 (0.65) | POLBKDM4ETSHRRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| CN-105980386-A | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2016-09-28 | — | — | CN | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | claimed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| EP-1131291-B1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | ROCHE BIOSCIENCE | 2003-08-14 | — | — | US | claimed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | claimed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | claimed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | claimed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | claimed |
| EP-1131291-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | claimed |
| US-6140344-A | FOR TREATING PATHOLOGICAL CONDITIONS SUCH AS ASTHMA, RHINITIS, ECZEMA AND PARASITIC INFECTIONS FEATURING TISSUE EOSINOPHILIA | SYNTEX (U.S.A.) INC. (US) | 2000-10-31 | — | — | US | claimed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | claimed |
| WO-2000029377-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | POLB 2395/4885KDM4E 12/4885TSHR 4550/4885 |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | POLB 3681/4885KDM4E 3302/4885TSHR 631/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | POLB 2395/4885KDM4E 12/4885TSHR 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.